15-Year watch: tracking patients after experimental cancer cell therapy
Disease control
Not yet recruiting
This study will monitor patients for 15 years after they received an experimental CAR-T cell therapy for relapsed or hard-to-treat blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The main goal is to understand the long-term safety of the treatm…
Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC